Role of Caspases in Inflammation-Driven Diseases

Design of Caspase Inhibitors as Potential Clinical Agents

Volumn , Issue , 2008, Pages 19-58

  Kersse, Kristof ^a   Berghe, Tom Vanden ^a   Lippens, Saskia ^a   Declercq, Wim ^a   Vandenabeele, Peter ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84655176135     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420045413-6     Document Type: Chapter

References (334)

1. Festjens, N., et al. 2006. Caspase-containing complexes in the regulation of cell death and inflammation. Biol Chem 387:1005-16.
2. Lamkanfi, M., et al. 2007. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 14: 44-55.
3. Lamkanfi, M., et al. 2002. Alice in caspase land. A phylogenetic analysis of caspases from worm to man. Cell Death Differ 9:358-61.
4. Boatright, K. M., et al. 2003. A unified model for apical caspase activation. Mol Cell 11:529-41.
5. Cerretti, D. P., et al. 1992. Molecular cloning of the interleukin-1 beta converting enzyme. Science 256:97-100.
6. Ghayur, T., et al. 1997. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386:619-23.
7. Schmitz, J., et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-90.
8. Thornberry, N. A., et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356:763-74.
9. Kuida, K., et al. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267: 2000-3.
10. Li, P., et al. 1995. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80:401-11.
11. Martinon, F., and Tschopp, J. 2007. Inflammatory caspases and inflammasomes: Master switches of inflammation. Cell Death Differ 14: 10-22.
12. Agostini, L., et al. 2004. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20:319-25.
13. Martinon, F., Burns, K., and Tschopp, J. 2002. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417-26.
14. Amer, A., et al. 2006. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem 281: 35217-23.
15. Boyden, E. D., and Dietrich, W. F. 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38: 240-4.
16. Franchi, L., et al. 2006. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 7: 576-82.
17. Kanneganti, T. D., et al. 2006. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 281: 36560-8.
18. Kanneganti, T. D., et al. 2006. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440:233-6.
19. Mariathasan, S., et al. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-32.
20. Martinon, F., et al. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-41.
21. Miao, E. A., et al. 2006. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 7:569-75.
22. Martinon, F., and Tschopp, J. 2005. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26:447-54.
23. Mariathasan, S., et al. 2004. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430:213-8.
24. Ting, J. P., and Davis, B. K. 2005. CATERPILLER: A novel gene family important in immunity, cell death, and diseases. Annu Rev Immunol 23:387-414.
25. Puren, A. J., Fantuzzi, G., and Dinarello, C. A. 1999. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci USA 96: 2256-61.
26. Kanneganti, T. D., et al. 2007. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26:433-43.
27. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87: 2095-147.
28. Dinarello, C. A. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16:457-99.
29. Bergman, M. R., et al. 2003. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 369:485-96.
30. Luo, L., Cruz, T., and McCulloch, C. 1997. Interleukin 1-induced calcium signalling in chondrocytes requires focal adhesions. Biochem J 324 (Pt 2):653-8.
31. Matthews, J. S., and O’Neill, L. A. 1999. Distinct roles for p42/p44 and p38 mitogenactivated protein kinases in the induction of IL-2 by IL-1. Cytokine 11: 643-55.
32. Palsson, E. M., et al. 2000. Divergent roles for Ras and Rap in the activation of p38 mitogen-activated protein kinase by interleukin-1. J Biol Chem 275:7818-25.
33. Shirakawa, F., et al. 1989. Interleukin 1 and cyclic AMP induce kappa immunoglobulin light-chain expression via activation of an NF-kappa B-like DNA-binding protein. Mol Cell Biol 9:959-64.
34. Shirakawa, F., and Mizel, S. B. 1989. In vitro activation and nuclear translocation of NF-kappa B catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. Mol Cell Biol 9:2424-30.
35. Zhu, P., et al. 1998. Regulation of interleukin 1 signalling through integrin binding and actin reorganization: Disparate effects on NF-kappaB and stress kinase pathways. Biochem J 330 (Pt 2):975-81.
36. Kersse, K., et al. 2007. A phylogenetic and functional overview of inflammatory caspases and caspase-1-related CARD-only proteins. Biochem Soc Trans 35:1508-11.
37. Druilhe, A., et al. 2001. Regulation of IL-1beta generation by pseudo-ICE and ICEBERG, two dominant negative caspase recruitment domain proteins. Cell Death Differ 8:649-57.
38. Humke, E. W., et al. 2000. ICEBERG: A novel inhibitor of interleukin-1beta generation. Cell 103:99-111.
39. Lamkanfi, M., et al. 2004. INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1beta generation. J Biol Chem 279: 51729-38.
40. Lee, S. H., Stehlik, C., and Reed, J. C. 2001. Cop, a caspase recruitment domaincontaining protein and inhibitor of caspase-1 activation processing. J Biol Chem 276: 34495-500.
41. Colotta, F., et al. 1993. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 261:472-5.
42. Lang, D., et al. 1998. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: A novel mechanism of regulation of IL-1 responsiveness. J Immunol 161:6871-7.
43. Giri, J. G., et al. 1994. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol 153:5862-9.
44. Smith, D. E., et al. 2003. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18:87-96.
45. Carter, D. B., et al. 1990. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344: 633-8.
46. Hannum, C. H., et al. 1990. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336-40.
47. Dao, T., Mehal, W. Z., and Crispe, I. N. 1998. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J Immunol 161:2217-22.
48. Micallef, M. J., et al. 1996. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 26:1647-51.
49. Okamura, H., et al. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378:88-91.
50. Yoshimoto, T., et al. 1998. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-gamma production. J Immunol 161:3400-7.
51. Horwood, N. J., et al. 1998. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 101:595-603.
52. Olee, T., et al. 1999. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol 162:1096-100.
53. Hoshino, K., et al. 1999. Cutting edge: Generation of IL-18 receptor-deficient mice: Evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 162:5041-4.
54. Parnet, P., et al. 1996. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem 271:3967-70.
55. Torigoe, K., et al. 1997. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 272:25737-42.
56. Barbulescu, K., et al. 1998. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol 160:3642-7.
57. Kalina, U., et al. 2000. IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21. J Immunol 165:1307-13.
58. Matsumoto, S., et al. 1997. Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. Biochem Biophys Res Commun 234:454-7.
59. Nakahira, M., et al. 2002. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 168:1146-53.
60. Robinson, D., et al. 1997. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 7:571-81.
61. Johansen, C., et al. 2007. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 127:2857-64.
62. Niyonsaba, F., et al. 2005. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol 175:1776-84.
63. Aizawa, Y., et al. 1999. Cloning and expression of interleukin-18 binding protein. FEBS Lett 445:338-42.
64. Novick, D., et al. 1999. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 10:127-36.
65. Kim, S. H., et al. 2002. Identification of amino acid residues critical for biological activity in human interleukin-18. J Biol Chem 277:10998-1003.
66. Kim, S. H., et al. 2000. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 97:1190-5.
67. Lawrence, R. C., et al. 1998. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778-99.
68. Felson, D. T. 2006. Clinical practice. Osteoarthritis of the knee. N Engl J Med 354:841-8.
69. Fernandes, J. C., Martel-Pelletier, J., and Pelletier, J. P. 2002. The role of cytokines in osteoarthritis pathophysiology. Biorheology 39:237-46.
70. Goldring, M. B. 1999. The role of cytokines as inflammatory mediators in osteoarthritis: Lessons from animal models. Connect Tissue Res 40:1-11.
71. Goldring, M. B. 2000. Osteoarthritis and cartilage: The role of cytokines. Curr Rheumatol Rep 2:459-65.
72. Pelletier, J. P., et al. 1995. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol Suppl 43:109-14.
73. Vuolteenaho, K., et al. 2002. Effects of TNFalpha-antagonists on nitric oxide production in human cartilage. Osteoarthritis Cartilage 10:327-32.
74. Gu, Y., et al. 1997. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275:206-9.
75. Saha, N., et al. 1999. Interleukin-1beta-converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1beta and interleukin-18. Arthritis Rheum 42:1577-87.
76. Futani, H., et al. 2002. Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: A potential therapeutic target of cartilage degradation. J Immunother 25 (Suppl 1):561-4.
77. Nouri, A. M., Panayi, G. S., and Goodman, S. M. 1984. Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 55:295-302.
78. Rudolphi, K., et al. 2003. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 11:738-46.
79. Caron, J. P., et al. 1996. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 39:1535-44.
80. Chevalier, X., et al. 2005. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: A multicenter study. J Rheumatol 32:1317-23.
81. Evans, C. H., et al. 2004. Osteoarthritis gene therapy. Gene Ther 11:379-89.
82. Gouze, J. N., et al. 2003. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer. Arthritis Res Ther 5:R301-9.
83. Iqbal, I., and Fleischmann, R. 2007. Treatment of osteoarthritis with anakinra. Curr Rheumatol Rep 9:31-5.
84. Zhang, X., Mao, Z., and Yu, C. 2004. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res 22:742-50.
85. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423:356-61.
86. Koch, A. E. 2007. The pathogenesis of rheumatoid arthritis. Am J Orthop 36:5-8.
87. Gabriel, S. E. 2001. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 27:269-81.
88. Lane, N. E. 2007. Clinical practice. Osteoarthritis of the hip. N Engl J Med 357: 1413-21.
89. McInnes, I. B., and Schett, G. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429-42.
90. Burger, D., et al. 2006. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 20:879-96.
91. Kay, J., and Calabrese, L. 2004. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 43(Suppl 3):iii2-iii9.
92. Westacott, C. I., et al. 1990. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 49:676-81.
93. Rosengren, S., et al. 2005. Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis 64:708-14.
94. Gabay, C., et al. 2001. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. Arthritis Rheum 44:451-62.
95. Van Lent, P. L., et al. 1995. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 22:2250-8.
96. van den Berg, W. B., et al. 1999. Role of tumour necrosis factor alpha in experimental arthritis: Separate activity of interleukin 1beta in chronicity and cartilage destruction. Ann Rheum Dis 58(Suppl 1):140-8.
97. Milner, J. M., and Cawston, T. E. 2005. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy 4:363-75.
98. Ma, Y., et al. 1998. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 41:1798-865.
99. Nakae, S., et al. 2001. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol 167:90-7.
100. Gracie, J. A., et al. 1999. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104:1393-401.
101. Joosten, L. A., et al. 2003. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 48:339-47.
102. Rooney, T., et al. 2004. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 63:1393-8.
103. Yamamura, M., et al. 2001. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275-85.
104. Petrovic-Rackov, L., and Pejnovic, N. 2006. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol 25:448-52.
105. Wei, X. Q., et al. 2001. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 166:517-21.
106. Joosten, L. A., et al. 2000. An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol 165:6553-8.
107. Pittoni, V., et al. 2002. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 61:723-5.
108. Tanaka, M., et al. 2001. Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells. J Rheumatol 28:1779-87.
109. Dai, S. M., et al. 2007. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis 66:1411-8.
110. Pavelka, K., et al. 2002. Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1β converting enzyme (ICE) inhibitor, in a 285 patient PhII trial in rheumatoid arthritis (RA). Arthritis Rheum 46:LB02.
111. Wannamaker, W., et al. 2007. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3, 3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R, 3S)-2-ethoxy-5-oxotetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther 321:509-16.
112. Ku, G., Ford, P., and Raybuck, S. A. 2002. Selective interleukin-1beta-converting enzyme (ICE/CASPASE-1) inhibition with pralnacasan (HMR 3480/VX-740) reduces inflammation and joint destruction in murine type II collegenase-induced arthritis. Arthritis Rheum 44:5241.
113. Arner, E. C., et al. 1995. Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit. J Rheumatol 22:1338-46.
114. Joosten, L. A., et al. 1999. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163:5049-55.
115. Joosten, L. A., et al. 1996. Anticytokine treatment of established type II collageninduced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 39:797-809.
116. Botsios, C., et al. 2007. [Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis]. Reumatismo 59:32-7.
117. Bresnihan, B., et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196-204.
118. Cohen, S., et al. 2002. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614-24.
119. Cohen, S. B., Woolley, J. M., and Chan, W. 2003. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 30:225-31.
120. Jiang, Y., et al. 2000. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43:1001-9.
121. Nixon, R., Bansback, N., and Brennan, A. 2007. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: A metaanalysis and adjusted indirect comparisons. Rheumatology (Oxford), 46:1146-7.
122. Dinarello, C. A. 2004. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 4:378-85.
123. Toussirot, E., and Wendling, D. 2007. The use of TNF-alpha blocking agents in rheumatoid arthritis: An update. Expert Opin Pharmacother 8:2089-107.
124. Plater-Zyberk, C., et al. 2001. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108:1825-32.
125. Mikuls, T. R., and Saag, K. G. 2006. New insights into gout epidemiology. Curr Opin Rheumatol 18:199-203.
126. Wallace, K. L., et al. 2004. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31:1582-7.
127. Dalbeth, N., and Haskard, D. O. 2005. Mechanisms of inflammation in gout. Rheumatology (Oxford) 44:1090-6.
128. Wu, X. W., et al. 1989. Urate oxidase: Primary structure and evolutionary implications. Proc Natl Acad Sci USA 86:4412-6.
129. Choi, H. K., et al. 2005. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch Intern Med 165:742-8.
130. Choi, H. K., and Curhan, G. 2005. Gout: Epidemiology and lifestyle choices. Curr Opin Rheumatol 17:341-5.
131. Derfus, B., et al. 1998. Human osteoarthritic cartilage matrix vesicles generate both calcium pyrophosphate dihydrate and apatite in vitro. Calcif Tissue Int 63:258-62.
132. Pay, S., and Terkeltaub, R. 2003. Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: New developments relevant to the clinician. Curr Rheumatol Rep 5:235-43.
133. Pritzker, K. P., Cheng, P. T., and Renlund, R. C. 1988. Calcium pyrophosphate crystal deposition in hyaline cartilage. Ultrastructural analysis and implications for pathogenesis. J Rheumatol 15:828-35.
134. Johnson, K., and Terkeltaub, R. 2005. Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage. Front Biosci 10:988-97.
135. Di Giovine, F. S., et al. 1987. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 138:3213-8.
136. Inokuchi, T., et al. 2006. Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18. Cytokine 33:21-7.
137. So, A., et al. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:1228.
138. Samuels, J., and Ozen, S. 2006. Familial Mediterranean fever and the other autoinflammatory syndromes: Evaluation of the patient with recurrent fever. Curr Opin Rheumatol 18:108-17.
139. Shinkai, K., McCalmont, T. H., and Leslie, K. S. 2007. Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 33:1-9.
140. Simon, A., and van der Meer, J. W. 2007. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 292:R86-98.
141. Aksentijevich, I., et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrinassociated autoinflammatory diseases. Arthritis Rheum 46:3340-8.
142. Dode, C., et al. 2002. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: A novel mutation underlies both syndromes. Am J Hum Genet 70:1498-506.
143. Feldmann, J., et al. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71:198-203.
144. Hoffman, H. M., et al. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29:301-5.
145. Zeft, A., and Bohnsack, J. F. 2007. Cryopyrin-associated autoinflammatory syndrome: A new mutation. Ann Rheum Dis 66:843-4.
146. Touitou, I., et al. 2004. Infevers: An evolving mutation database for auto-inflammatory syndromes. Hum Mutat 24:194-8.
147. Rosengren, S., et al. 2007. Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia. J Allergy Clin Immunol 119:991-6.
148. Hawkins, P. N., Lachmann, H. J., and McDermott, M. F. 2003. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348:2583-4.
149. Duncan, J. A., et al. 2007. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci USA 104:8041-6.
150. Tameling, W. I., et al. 2006. Mutations in the NB-ARC domain of I-2 that impair ATP hydrolysis cause autoactivation. Plant Physiol 140:1233-45.
151. Gattorno, M., et al. 2007. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 56:3138-48.
152. Thornton, B. D., et al. 2007. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin-1 receptor antagonist. Am J Kidney Dis 49:477-81.
153. Arostegui, J. I., et al. 2004. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum 50:4045-50.
154. Boschan, C., et al. 2006. Neonatal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. Am J Med Genet A 140:883-6.
155. Caroli, F., et al. 2007. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 46:473-8.
156. Goldbach-Mansky, R., et al. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581-92.
157. Hawkins, P. N., et al. 2004. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum 50:2708-9.
158. Hawkins, P. N., et al. 2004. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50:607-12.
159. Hoffman, H. M., et al. 2004. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779-85.
160. Leslie, K. S., et al. 2006. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 142:1591-7.
161. Ramos, E., et al. 2005. Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS). Rheumatology (Oxford) 44:1072-3.
162. Stack, J. H., et al. 2005. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 175:2630-V.
163. Onen, F. 2006. Familial Mediterranean fever. Rheumatol Int 26:489-96.
164. Yepiskoposyan, L., and Harutyunyan, A. 2007. Population genetics of familial Mediterranean fever: A review. Eur J Hum Genet 15:911-6.
165. Schaner, P., et al. 2001. Episodic evolution of pyrin in primates: Human mutations recapitulate ancestral amino acid states. Nat Genet 27:318-21.
166. Chae, J. J., et al. 2003. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 11:591-604.
167. Chae, J. J., et al. 2006. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 103:9982-7.
168. Papin, S., et al. 2007. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 14:1457-66.
169. Yu, J. W., et al. 2006. Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ 13:236-49.
170. Woo, J. S., et al. 2006. Structural and functional insights into the B30.2/SPRY domain. EMBO J 25:1353-63.
171. Calligaris, L., et al. 2007. The efficacy of anakinra in an adolescent with colchicineresistant familial Mediterranean fever. Eur J Pediatr. 167:645-696.
172. Lindor, N. M., et al. 1997. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72:611-5.
173. Tallon, B., and Corkill, M. 2006. Peculiarities of PAPA syndrome. Rheumatology (Oxford) 45:1140-3.
174. Spencer, S., et al. 1997. PSTPIP: A tyrosine phosphorylated cleavage furrowassociated protein that is a substrate for a PEST tyrosine phosphatase. J Cell Biol 138:845-60.
175. Wise, C. A., et al. 2002. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11:961-9.
176. Shoham, N. G., et al. 2003. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 100:13501-6.
177. Yu, J. W., et al. 2007. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 28:214-27.
178. Fernandes-Alnemri, T., et al. 2007. The pyroptosome: A supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 14:1590-604.
179. Dierselhuis, M. P., et al. 2005. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 44:406-8.
180. Podolsky, D. K. 2002. Inflammatory bowel disease. N Engl J Med 347:417-29.
181. Xavier, R. J., and Podolsky, D. K. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427-34.
182. Sartor, R. B. 2006. Mechanisms of disease: Pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3:390-407.
183. Lakatos, P. L. 2006. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? World J Gastroenterol 12:6102-8.
184. Halme, L., et al. 2006. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 12:3668-72.
185. Duerr, R. H., et al. 2006. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461-3.
186. Franke, A., et al. 2007. Systematic association mapping identifies NELL1 as a novel IBD disease gene. PLoS ONE 2:c691.
187. Hampe, J., et al. 2007. A genome-wide association scan of nonsynonymous SNP’s identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39:207-11.
188. Hugot, J. P., et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599-603.
189. Ogura, Y., et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411:603-6.
190. Peltekova, V. D., et al. 2004. Functional variants of OCTN cation transporter genes are associated with Crohn’s disease. Nat Genet 36.
191. Stoll, M., et al. 2004. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36:471-5.
192. Kanneganti, T. D., Lamkanfi, M., and Nunez, G. 2007. Intracellular NOD-like receptors in host defense and disease. Immunity 27:549-59.
193. Barnich, N., et al. 2005. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-kB activation in muramyl dipeptide recognition. J Cell Biol 170:21-6.
194. Lecine, P., et al. 2007. The NOD2-RICK complex signals from the plasma membrane. J Biol Chem 282:15197-207.
195. Girardin, S. E., et al. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278:8869-72.
196. Girardin, S. E., et al. 2003. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 278:41702-8.
197. Inohara, N., et al. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 278:5509-12.
198. Ogura, Y., et al. 2001. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276:4812-18.
199. Ferwerda, G., et al. 2005. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog, 1:279-85.
200. Kobayashi, K. S., et al. 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307:731-4.
201. Opitz, B., et al. 2004. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 279:36426-32.
202. Hsu, Y. M., et al. 2007. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol 8:198-205.
203. Park, J. H., et al. 2007. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 178:2380-6.
204. Yang, Y., et al. 2007. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem. 282:36223-9.
205. Underhill, D. M., and Shimada, T. 2007. A pair of 9s: It’s in the CARDs. Nat Immunol 8:122-4.
206. Strober, W., Fuss, I., and Mannon, P. 2007. The fundamental basis of inflammatory bowel disease. J Clin Invest 117:514-21.
207. Li, J., et al. 2004. Regulation of IL-8 and IL-1beta expression in Crohn’s disease associated NOD2/CARD15 mutations. Hum Mol Genet 13:1715-25.
208. Rakoff-Nahoum, S., et al. 2004. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229-41.
209. Hedl, M., et al. 2007. Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci USA 104:19440-5.
210. Uehara, A., et al. 2007. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 44:3100-11.
211. Yang, Z., et al. 2007. NOD2 transgenic mice exhibit enhanced MDP-mediated downregulation of TLR2 responses and resistance to colitis induction. Gastroenterology 133:1510-12.
212. Maeda, S., et al. 2005. Nod 2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science 307:734-8.
213. Damiano, J. S., et al. 2004. Heterotypic interactions among NACHT domains: Implications for regulation of innate immune responses. Biochem J 381:213-9.
214. Pan, Q., et al. 2007. MDP-induced interleukin-1beta processing requires Nod 2 and CIAS1/NALP3. J Leukoc Biol 82:177-83.
215. Watanabe, T., et al. 2006. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 25:473-85.
216. Netea, M. G., et al. 2005. NOD2 3020insC mutation and the pathogenesis of Crohn’s disease: Impaired IL-1beta production points to a loss-of-function phenotype. Neth J Med 63:305-8.
217. van Heel, D. A., et al. 2005. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet 365:1794-6.
218. Siegmund, B. 2002. Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol 64:1-8.
219. Siegmund, B., et al. 2001. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 98:13249-54.
220. Monteleone, G., et al. 1999. Bioactive IL-18 expression is up-regulated in Crohn’s disease. J Immunol 163:143-7.
221. Pages, F., et al. 2001. Analysis of interleukin-18, interleukin-1 converting enzyme (ICE) and interleukin-18-related cytokines in Crohn’s disease lesions. Eur Cytokine Netw 12:97-104.
222. Pizarro, T. T., et al. 1999. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: Expression and localization in intestinal mucosal cells. J Immunol 162:6829-35.
223. McAlindon, M. E., et al. 1999. Investigation of the expression of IL-1beta converting enzyme and apoptosis in normal and inflammatory bowel disease (IBD) mucosal macrophages. Clin Exp Immunol 116:251-7.
224. McAlindon, M. E., Hawkey, C. J., and Mahida, Y. R. 1998. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 42:214-9.
225. Carter, J. D., Valeriano, J., and Vasey, F. B. 2003. Crohn disease worsened by anakinra administration. J Clin Rheumatol 9:276-7.
226. Bauer, C., et al. 2007. The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci 52:1642-52.
227. Loher, F., et al. 2004. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 308:583-90.
228. Bone, R. C., et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-55.
229. Hotchkiss, R. S., and Karl, I. E. 2003. The pathophysiology and treatment of sepsis. N Engl J Med 348:138-50.
230. Levy, M. M., et al. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530-8.
231. Vincent, J. L., et al. 2006. Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 34:344-53.
232. Sarkar, A., et al. 2006. Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am J Respir Crit Care Med 174:1003-10.
233. Fantuzzi, G., et al. 1996. Effect of endotoxin in IL-1 beta-deficient mice. J Immunol 157:291-6.
234. Hotchkiss, R. S., and Nicholson, D. W. 2006. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6:813-22.
235. Fisher, C. J., Jr., et al. 1994. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12-21.
236. Zeni, F., Freeman, B., and Natanson, C. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25:1095-100.
237. Medzhitov, R. 2007. Recognition of microorganisms and activation of the immune response. Nature 449:819-26.
238. Kupper, T. S., and Fuhlbrigge, R. C. 2004. Immune surveillance in the skin: Mechanisms and clinical consequences. Nat Rev Immunol 4:211-22.
239. Companjen, A., et al. 2004. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. Eur Cytokine Netw 15:210-6.
240. Debets, R., et al. 1997. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 158:2955-63.
241. Mee, J. B., et al. 2007. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: Dominance of innate immune responses in psoriasis. Am J Pathol 171:32-42.
242. Kong, J., Grando, S. A., and Li, Y. C. 2006. Regulation of IL-1 family cytokines IL-1alpha, IL-1 receptor antagonist, and IL-18 by 1, 25-dihydroxyvitamin D3 in primary keratinocytes. J Immunol 176:3780-7.
243. Shepherd, J., Little, M. C., and Nicklin, M. J. 2004. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol 122:665-9.
244. Antonopoulos, C., et al. 2001. Functional caspase-1 is required for Langerhans cell migration and optimal contact sensitization in mice. J Immunol 166:3672-7.
245. Watanabe, H., et al. 2007. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 127:1956-63.
246. Antonopoulos, C., et al. 2007. IL-18 is a key proximal mediator of contact hypersensitivity and allergen-induced Langerhans cell migration in murine epidermis. J Leukoc Biol. 83.
247. Jin, Y., et al. 2007. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356:1216-25.
248. Allan, S. M., Tyrrell, P. J., and Rothwell, N. J. 2005. Interleukin-1 and neuronal injury. Nat Rev Immunol 5:629-40.
249. Simi, A., et al. 2007. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 35:1122-6.
250. Lucas, S. M., Rothwell, N. J., and Gibson, R. M. 2006. The role of inflammation in CNS injury and disease. Br J Pharmacol 147(Suppl 1):5232-40.
251. Felderhoff-Mueser, U., et al. 2005. IL-18: A key player in neuroinflammation and neurodegeneration? Trends Neurosci 28:487-93.
252. Fassbender, K., et al. 1994. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: Kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 122:135-9.
253. Tarkowski, E., et al. 1995. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 26:1393-8.
254. Friedlander, R. M., et al. 1997. Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med 185:933-40.
255. Hara, H., et al. 1997. Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J Cereb Blood Flow Metab 17:370-5.
256. Schielke, G. P., et al. 1998. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow Metab 18:180-5.
257. Rabuffetti, M., et al. 2000. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci 20:4398-404.
258. Mulcahy, N. J., et al. 2003. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 140:471-6.
259. Clark, S. R., et al. 2007. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab 28:387-94.
260. Gueorguieva, I., et al. 2007. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol 65:317-25.
261. Gutierrez, E. G., Banks, W. A., and Kastin, A. J. 1994. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol 55:153-60.
262. Touzani, O., et al. 1999. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol 100:203-15.
263. Emsley, H. C., et al. 2005. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 76:1366-72.
264. Ross, J., et al. 2007. A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology 53:638-42.
265. Adelson, P. D., and Kochanek, P. M. 1998. Head injury in children. J Child Neurol 13:2-15.
266. Masson, F., et al. 2001. Epidemiology of severe brain injuries: A prospective population-based study. J Trauma 51:481-9.
267. Bittigau, P., et al. 2003. Neuropathological and biochemical features of traumatic injury in the developing brain. Neurotoxicol Res 5:475-90.
268. Chan, P. H., et al. 1994. SOD-1 transgenic mice as a model for studies of neuroprotection in stroke and brain trauma. Ann NY Acad Sci 738:93-103.
269. Chen, Y., et al. 1996. An experimental model of closed head injury in mice: Pathophysiology, histopathology, and cognitive deficits. J Neurotrauma 13:557-68.
270. Jones, N. C., et al. 2004. A detrimental role for nitric oxide synthase-2 in the pathology resulting from acute cerebral injury. J Neuropathol Exp Neurol 63:708-20.
271. Fink, K. B., et al. 1999. Reduction of post-traumatic brain injury and free radical production by inhibition of the caspase-1 cascade. Neuroscience 94:1213-8.
272. Jones, N. C., et al. 2005. Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes. Eur J Neurosci 22:72-8.
273. Tehranian, R., et al. 2002. Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 19:939-51.
274. Yatsiv, I., et al. 2002. Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J Cereb Blood Flow Metab 22:971-8.
275. Tasci, A., et al. 2003. Prognostic value of interleukin-1 beta levels after acute brain injury. Neurol Res 25:871-4.
276. Sifringer, M., et al. 2007. Activation of caspase-1 dependent interleukins in developmental brain trauma. Neurobiol Dis 25:614-22.
277. Vezzani, A., and Granata, T. 2005. Brain inflammation in epilepsy: Experimental and clinical evidence. Epilepsia 46:1724-43.
278. Nadler, J. V. 1981. Minireview. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci 29:2031-42.
279. Olney, J. W., Rhee, V., and Ho, O. L. 1974. Kainic acid: A powerful neurotoxic analogue of glutamate. Brain Res 77:507-12.
280. Ravizza, T., et al. 2006. Inactivation of caspase-1 in rodent brain: A novel anticonvulsive strategy. Epilepsia 47:1160-8.
281. De Simoni, M. G., et al. 2000. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 12:2623-33.
282. Vezzani, A., et al. 2000. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci USA 97:11534-9.
283. Vezzani, A., et al. 2002. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 43(Suppl 5):30-5.
284. Glenner, G. G., and Wong, C. W. 1984. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-90.
285. Griffin, W. S., et al. 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611-5.
286. Ojala, J., et al. 2007. Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol Aging.
287. Wyss-Coray, T. 2006. Inflammation in Alzheimer’s disease: Driving force, bystander or beneficial response? Nat Med 12:1005-15.
288. Zhu, S. G., et al. 1999. Increased interleukin-1beta converting enzyme expression and activity in Alzheimer disease. J Neuropathol Exp Neurol 58:582-7.
289. Vandenabeele, P., and Fiers, W. 1991. Is amyloidogenesis during Alzheimer’s disease due to an IL-1-/IL-6-mediated “acute phase response” in the brain? Immunol Today 12:217-9.
290. Shaftel, S. S., et al. 2007. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117:1595-604.
291. Fahn, S. 2003. Description of Parkinson’s disease as a clinical syndrome. Ann NY Acad Sci 991:1-14.
292. Lang, A. E., and Lozano, A. M. 1998. Parkinson’s disease. First of two parts. N Engl J Med 339:1044-53.
293. Lang, A. E., and Lozano, A. M. 1998. Parkinson’s disease. Second of two parts. N Engl J Med 339:1130-43.
294. Moore, D. J., et al. 2005. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28:57-87.
295. Uhl, G. R., Hedreen, J. C., and Price, D. L. 1985. Parkinson’s disease: Loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35:1215-8.
296. Tansey, M. G., McCoy, M. K., and Frank-Cannon, T. C. 2007. Neuroinflammatory mechanisms in Parkinson’s disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208:1-25.
297. Blum-Degen, D., et al. 1995. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202:17-20.
298. Mogi, M., et al. 1994. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147-50.
299. Ferrari, C. C., et al. 2006 Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis 24: 183-193.
300. Mogi, M., et al. 2000. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm 107:335-41.
301. Kahns, S., et al. 2003. Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J Biol Chem 278:23376-80.
302. Lucking, C. B., et al. 2000. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 342:1560-7.
303. Shimura, H., et al. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302-5.
304. Du, Y., et al. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci USA 98:14669-74.
305. McFarland, H. F., and Martin, R. 2007. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 8:913-9.
306. Noseworthy, J. H. 1999. Progress in determining the causes and treatment of multiple sclerosis. Nature 399:A40-7.
307. Pollak, Y., et al. 2002. Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of “depression due to multiple sclerosis.” Brain Behav Immun 16:533-43.
308. Olsson, T. 1995. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 144:245-68.
309. Bauer, J., et al. 1993. Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level. J Neuroimmunol 48:13-21.
310. Brosnan, C. F., et al. 1995. Cytokine localization in multiple sclerosis lesions: Correlation with adhesion molecule expression and reactive nitrogen species. Neurology 45:516-21.
311. Losy, J., and Niezgoda, A. 2001. IL-18 in patients with multiple sclerosis. Acta Neurol Scand 104:171-3.
312. Maimone, D., et al. 1991. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32:67-74.
313. Nicoletti, F., et al. 2001. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 57:342-4.
314. Villarroya, H., et al. 1996. Myelin-induced experimental allergic encephalomyelitis in Lewis rats: Tumor necrosis factor alpha levels in serum and cerebrospinal fluid immunohistochemical expression in glial cells and macrophages of optic nerve and spinal cord. J Neuroimmunol 64:55-61.
315. Furlan, R., et al. 1999. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 163:2403-9.
316. Ming, X., et al. 2002. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci 197:9-18.
317. Badovinac, V., et al. 1998. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol 85:87-95.
318. Martin, D., and Near, S. L. 1995. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol 61:241-5.
319. Pollak, Y., et al. 2003. The EAE-associated behavioral syndrome. II. Modulation by anti-inflammatory treatments. J Neuroimmunol 137:100-8.
320. Schiffenbauer, J., et al. 2000. The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin Immunol 95:117-23.
321. Wiemann, B., et al. 1998. Combined treatment of acute EAE in Lewis rats with TNFbinding protein and interleukin-1 receptor antagonist. Exp Neurol 149:455-63.
322. Wildbaum, G., et al. 1998. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J Immunol 161:6368-74.
323. Furlan, R., et al. 2007. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 14:93-8.
324. Rowland, L. P. 1998. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 160(Suppl 1): 56-24.
325. Gurney, M. E., et al. 1994. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264:1772-5.
326. Ripps, M. E., et al. 1995. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 92:689-93.
327. Wong, P. C., et al. 1995. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14:1105-16.
328. Li, M., et al. 2000. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288:335-9.
329. Yoshihara, T., et al. 2002. Differential expression of inflammation- and apoptosisrelated genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80:158-67.
330. Pasinelli, P., et al. 1998. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 95:15763-8.
331. Pasinelli, P., et al. 2000. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 97:13901-6.
332. Ilzecka, J., Stelmasiak, Z., and Dobosz, B. 2001. Interleukin-1beta converting enzyme/caspase-1 (ICE/caspase-1) and soluble APO-1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients. Acta Neurol Scand 103:255-8.
333. Martin, L. J., et al. 2000. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death [Review]. Int J Mol Med 5:3-13.
334. Friedlander, R. M., et al. 1997. Inhibition of ICE slows ALS in mice. Nature 388:31.